Integer Appoints Michael Coyle to Board of Directors
Integer Holdings (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), has appointed Michael Coyle to its Board of Directors. Coyle, who brings over 40 years of medical device industry experience, will serve on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
Coyle's extensive background includes serving as president and CEO of iRhythm Technologies, executive vice president at Medtronic's cardio and vascular group, and leadership roles at St. Jude Medical and Eli Lilly. He currently serves on the boards of Haemonetics Corporation and BaroPace, and holds six U.S. patents in cardiovascular medical device technologies.
Integer Holdings (NYSE:ITGR), un'importante organizzazione di sviluppo e produzione su contratto di dispositivi medici (CDMO), ha nominato Michael Coyle nel suo Consiglio di Amministrazione. Coyle, con oltre 40 anni di esperienza nel settore dei dispositivi medici, far脿 parte del Comitato di Revisione, del Comitato per la Retribuzione e l'Organizzazione e del Comitato per la Strategia Tecnologica.
Il vasto percorso professionale di Coyle include la carica di presidente e CEO di iRhythm Technologies, vicepresidente esecutivo del gruppo cardio e vascolare di Medtronic, oltre a ruoli di leadership presso St. Jude Medical ed Eli Lilly. Attualmente 猫 membro dei consigli di amministrazione di Haemonetics Corporation e BaroPace, e detiene sei brevetti statunitensi nelle tecnologie dei dispositivi medici cardiovascolari.
Integer Holdings (NYSE:ITGR), una destacada organizaci贸n de desarrollo y fabricaci贸n por contrato de dispositivos m茅dicos (CDMO), ha nombrado a Michael Coyle en su Junta Directiva. Coyle, con m谩s de 40 a帽os de experiencia en la industria de dispositivos m茅dicos, formar谩 parte del Comit茅 de Auditor铆a, del Comit茅 de Compensaci贸n y Organizaci贸n, y del Comit茅 de Estrategia Tecnol贸gica.
La amplia trayectoria de Coyle incluye haber sido presidente y CEO de iRhythm Technologies, vicepresidente ejecutivo del grupo cardiovascular de Medtronic, y cargos de liderazgo en St. Jude Medical y Eli Lilly. Actualmente, forma parte de los consejos de administraci贸n de Haemonetics Corporation y BaroPace, y posee seis patentes estadounidenses en tecnolog铆as de dispositivos m茅dicos cardiovasculares.
Integer Holdings (NYSE:ITGR)電� 靹犽弰鞝侅澑 鞚橂旮瓣赴 瓿勳暯 臧滊皽 氚� 鞝滌“ 臁办(CDMO)鞙茧靹� Michael Coyle鞚� 鞚挫偓須岇棎 鞛勲獏頄堨姷雼堧嫟. Coyle鞚� 40雲� 鞚挫儊鞚� 鞚橂旮瓣赴 靷办梾 瓴诫牓鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 臧愳偓鞙勳洂須�, 氤挫儊 氚� 臁办鞙勳洂須�, 旮办垹 鞝勲灥鞙勳洂須岇棎靹� 頇滊彊頃� 鞓堨爼鞛呺媹雼�.
Coyle鞚� 韽創鞚� 瓴诫牓鞐愲姅 iRhythm Technologies鞚� 靷灔 瓴� CEO, Medtronic 鞁槇甏� 攴鸽９鞚� 攵�靷灔, St. Jude Medical 氚� Eli Lilly鞐愳劀鞚� 毽崝鞁� 鞐暊鞚� 韽暔霅╇媹雼�. 順勳灛 Haemonetics Corporation瓿� BaroPace 鞚挫偓須岇棎靹� 頇滊彊 欷戩澊氅�, 鞁槇甏� 鞚橂旮瓣赴 旮办垹 攵勳暭鞐愳劀 6瓯挫潣 氙戈淡 韸鬼棃毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Integer Holdings (NYSE:ITGR), une organisation leader dans le d茅veloppement et la fabrication sous contrat de dispositifs m茅dicaux (CDMO), a nomm茅 Michael Coyle 脿 son conseil d'administration. Coyle, qui poss猫de plus de 40 ans d'exp茅rience dans l'industrie des dispositifs m茅dicaux, si茅gera au comit茅 d'audit, au comit茅 de r茅mun茅ration et d'organisation, ainsi qu'au comit茅 de strat茅gie technologique.
Le parcours 茅tendu de Coyle inclut des postes de pr茅sident et CEO chez iRhythm Technologies, de vice-pr茅sident ex茅cutif du groupe cardio-vasculaire chez Medtronic, ainsi que des r么les de direction chez St. Jude Medical et Eli Lilly. Il si猫ge actuellement aux conseils d'administration de Haemonetics Corporation et BaroPace, et d茅tient six brevets am茅ricains dans les technologies des dispositifs m茅dicaux cardiovasculaires.
Integer Holdings (NYSE:ITGR), ein f眉hrendes Unternehmen im Bereich der Vertragsentwicklung und -fertigung von Medizinprodukten (CDMO), hat Michael Coyle in seinen Vorstand berufen. Coyle bringt 眉ber 40 Jahre Erfahrung in der Medizinproduktebranche mit und wird im Pr眉fungsausschuss, im Verg眉tungs- und Organisationsausschuss sowie im Ausschuss f眉r Technologiestrategie t盲tig sein.
Coyles umfangreicher Hintergrund umfasst die Positionen als Pr盲sident und CEO von iRhythm Technologies, Executive Vice President der kardiovaskul盲ren Gruppe bei Medtronic sowie F眉hrungsrollen bei St. Jude Medical und Eli Lilly. Derzeit sitzt er im Vorstand von Haemonetics Corporation und BaroPace und h盲lt sechs US-Patente im Bereich kardiovaskul盲rer Medizintechnologien.
- Appointment of highly experienced medical device industry veteran with 40+ years of leadership
- New director brings valuable expertise in cardiovascular technologies with 6 U.S. patents
- Strategic addition to strengthen board oversight in technology and medical device manufacturing
- None.
~ New Director Brings Extensive Medical Device Industry Leadership and聽Technology Experience to Integer Board ~
PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors.
Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Before that, he was executive vice president and group president of Medtronic鈥檚 cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career.
Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies, Inc. and Volcano Corporation.
He earned a master's degree in business administration from the聽Wharton School of Business,聽University of Pennsylvania, and a bachelor's degree from聽Case Western Reserve University. He additionally holds six聽U.S.聽patents聽related to cardiovascular medical device products and technologies.
鈥淚nteger鈥檚 Board regularly evaluates its composition to ensure it encompasses the appropriate skills, background and perspectives necessary to drive growth for Integer鈥檚 shareholders,鈥� said Pamela Bailey, Integer Board Chair. 鈥淲e are pleased to welcome Michael Coyle, whose extensive medical device industry experience and proven leadership in global business and technology will contribute significantly to our strategic initiatives and culture.鈥�
鈥淭he executive leadership team and I look forward to working with Michael as we execute our strategy to deliver sustained outperformance,鈥� said Joseph Dziedzic, Integer president and CEO. 鈥淲e are confident Michael's expertise will contribute to Integer鈥檚 contract development and manufacturing outsourcing strategy, furthering our position as our customers鈥� partner of choice for innovative medical technologies and services as we realize our vision to enhance the lives of patients worldwide.鈥�
About Integer庐
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical庐 and Lake Region Medical庐. Additional information is available at .
| Investor Relations: | Media Relations: |
| Kristen Stewart | Kelly Butler |
| [email protected] | [email protected] |
| 551.337.3973 | 469.731.6617 |
FAQ
Who is Michael Coyle, the new board member of Integer Holdings (NYSE:ITGR)?
What committees will Michael Coyle serve on Integer's Board?
What is Michael Coyle's educational background?
What other board positions does Michael Coyle currently hold?
